Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
Public ClinicalTrials.gov record NCT00322270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter, Multinational, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects With Occluded Central Venous Access Devices (SONOMA-3)
Study identification
- NCT ID
- NCT00322270
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- ARCA Biopharma, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Alfimeprase Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2005
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Aug 14, 2008
Started 2006
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Desert Oasis Cancer Center | Casa Grande | Arizona | 85222 | — |
| Cancer Research & Prevention Center | Soquel | California | 95073 | — |
| Bethesda Research Center | Boynton Beach | Florida | 33435 | — |
| Pasco Hernando Oncology Associates | Brooksville | Florida | 34613 | — |
| Mercy Hospital | Miami | Florida | 33133 | — |
| Pasco Hernando Oncology Associate | New Port Richey | Florida | 34652 | — |
| Medical and Surgical Specialists | Galesburg | Illinois | 61401 | — |
| Cancer Center at Blessing Hospital | Quincy | Illinois | 62301 | — |
| Kalamazoo Hematology and Oncology | Kalamazoo | Michigan | 49048 | — |
| Sparrow Cancer Center | Lansing | Michigan | 48912 | — |
| Comprehensive Cancer Care Clinic | Jefferson City | Missouri | 65109 | — |
| The Center for Cancer Care and Research | St Louis | Missouri | 63141 | — |
| UMDNJ-Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
| Dakota Cancer Institute | Fargo | North Dakota | 58103 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Hematology/Oncology Consultants, Inc. | Columbus | Ohio | 43235 | — |
| Texas Oncology, P.A. | Dallas | Texas | 75230 | — |
| Carilion Gynecology/Oncology | Roanoke | Virginia | 24074 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00322270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2008 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00322270 live on ClinicalTrials.gov.